For nearly two decades, how kidney cancer becomes resistant to rapalog drugs has baffled the scientific community. Now, a study by researchers at UT Southwestern Medical Center’s Kidney Cancer Program sheds light.
Researchers from City of Hope, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, the University of Pennsylvania, and NIH have developed a way to add features to T cells to help them overcome mechanisms of chimeric antigen receptor T-cell therapy resistance. The new system is outlined in a paper published in Nature Biomedical Engineering.
